Saxenda(R) Demonstrated Improvements in BMI and Body Weight in...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
BAGSVÆRD, Denmark, April 1, 2020 /PRNewswire-AsiaNet/ -- Novo Nordisk today announced that the New England Journal of Medicine published results of a phase 3 trial evaluating the investigational use of Saxenda(R) (liraglutide 3.0 mg) in adolescents (aged 12 – 18) with obesity.[1] The study was accepted ...
Authors: LATEST ASIANET NEWS RELEASES